HIN-1: a New Epigenetic Biomarker Crucial for Therapy Selection in Glioblastoma Multiforme.
Glioblastoma multiforme (GBM) is the most common brain tumor in adults. The role of high in normal-1 (HIN-1) as a potential biomarker in combating this disease is being described for the first time in this study. A combination of O6-methylguanine DNA methyltransferase (MGMT) and HIN-1 methylation could be a possible biomarker in therapy choice. Interestingly, survival data shows a similar trend for the methylation of MGMT and for unmethylation of HIN-1 and vice versa. Eighty-eight paraffin-embedded brain tumors were analyzed to screen methylation rates of different genes and evaluate the association between genes methylation and clinicopathologic variables. Our study is the first of its kind to indicate that MGMT and HIN-1 methylation status are inverted (97.7% of methylated ones) and could be new markers in the study of GBM prognosis, especially in the therapy selection.
Nuclear Medicine Department, Molecular Imaging Program, IDIS, USC, Hospital Clínico Universitario. Fundación Tejerina, Santiago de Compostela, Spain. michel.herranz.carnero@sergas.es.
M
M
Herranz
Department of Functional Biology and Health Sciences, Human Anatomy and Embryology Section, University of Vigo, Vigo, Pontevedra, Spain.
M E
ME
Padín-Iruegas
Medical Oncology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain.
Nieves
N
Martínez-Lago
Medical Oncology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain.
S Aguín
SA
Losada
Medical Oncology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain.
P
P
Raña-Díez
Medical Oncology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain.
E Brozos
EB
Vázquez
Pathology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain.
J J
JJ
Carrera
Pathology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain.
J R
JR
Antúnez
Nuclear Medicine Department, Molecular Imaging Program, IDIS, USC, Hospital Clínico Universitario. Fundación Tejerina, Santiago de Compostela, Spain.
A
A
Ruibal
Medical Oncology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain.
R
R
López-López
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000378:metabolism; D001932:Brain Neoplasms / Q000235:genetics* / Q000628:therapy*; D016207:Cytokines / Q000378:metabolism*; D019175:DNA Methylation / Q000235:genetics; D044127:Epigenesis, Genetic; D005260:Female; D005909:Glioblastoma / Q000235:genetics* / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D025521:Tumor Suppressor Proteins / Q000378:metabolism*
D015415:Biomarkers; D016207:Cytokines; C434732:SCGB3A1 protein, human; D025521:Tumor Suppressor Proteins
Epigenetics; Glioblastoma; HIN1; Outcome; Therapy